
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-448
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : CHU de Quebec-Universite Laval | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Laval University | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Totum-448 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Totum-448
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : CHU de Quebec-Universite Laval | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Laval University | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of the Food Supplement TOTUM-070 on Lipid Metabolism
Details : Totum-070 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Totum-070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-448
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Clinic'n'Cell | University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Details : Totum-448 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 21, 2023
Lead Product(s) : Totum-448
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Clinic'n'Cell | University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TOTUM•63
Therapeutic Area : Endocrinology
Study Phase : Phase II/ Phase III
Sponsor : Nestle Health Sciences SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 22, 2023
Lead Product(s) : TOTUM•63
Therapeutic Area : Endocrinology
Highest Development Status : Phase II/ Phase III
Sponsor : Nestle Health Sciences SA
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : TP ICAP Midcap
Deal Size : $10.0 million
Deal Type : Public Offering
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
Details : TOTUM•070 is a combination of plant extracts, with no phytosterol or red yeast rice content. TOTUM•070 is being developed with a view to obtaining a proprietary health claim relating to the reduction of blood LDL cholesterol, a risk factor for cardio...
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : TOTUM•070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : TP ICAP Midcap
Deal Size : $10.0 million
Deal Type : Public Offering

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-070
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Totum-070 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Totum-070
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Excelya
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
Details : Totum-854 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prehypertension.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Totum-854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Excelya
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk
Details : Totum-63 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prediabetic State.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Totum-63
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Laval University | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Valbiotis Canada inc.
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Totum-854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : BioTeSys GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
To Assess TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
Details : Totum-854 is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Totum-854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : BioTeSys GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All